| Ticker Details |
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases.
|
| IPO Date: |
October 5, 2001 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.85B |
| Activated in VL: |
False |
| Average Daily Range |
| Avg Daily Range: |
$0.17 | 3.60%
|
| Avg Daily Range (30 D): |
$0.03 | 0.11%
|
| Avg Daily Range (90 D): |
$0.22 | 0.77%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.87M |
| Avg Daily Volume (30 D): |
.38M |
| Avg Daily Volume (90 D): |
1.46M |
| Trade Size |
| Avg Trade Size (Sh.): |
145 |
| Avg Trade Size (Sh.) (30 D): |
470 |
| Avg Trade Size (Sh.) (90 D): |
129 |
| Institutional Trades |
| Total Institutional Trades: |
2,974 |
| Avg Institutional Trade: |
$2.98M |
| Avg Institutional Trade (30 D): |
$8.05M |
| Avg Institutional Trade (90 D): |
$4.18M |
| Avg Institutional Trade Volume: |
.2M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.02M |
| Avg Closing Trade (30 D): |
$67.35M |
| Avg Closing Trade (90 D): |
$12.09M |
| Avg Closing Volume: |
276.21K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$1.81
|
$.52
|
$.43
|
|
Diluted EPS
|
$1.74
|
$.5
|
$.41
|
|
Revenue
|
$596.96M
|
$149.39M
|
$152.61M
|
|
Gross Profit
|
$513.14M
|
$134.92M
|
$126.54M
|
|
Net Income / Loss
|
$221.32M
|
$63.73M
|
$52.7M
|
|
Operating Income / Loss
|
$267.64M
|
$73.23M
|
$61.85M
|
|
Cost of Revenue
|
$83.82M
|
$14.48M
|
$26.07M
|
|
Net Cash Flow
|
$238.31M
|
$46.69M
|
$19.28M
|
|
PE Ratio
|
|
|
|
|
|
|
